Literature DB >> 12699683

Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells.

Michael Stöcker1, Mehmet K Tur, Stefanie Sasse, Anne Krüssmann, Stefan Barth, Andreas Engert.   

Abstract

Immunotoxins consist of a target-cell-specific binding moiety, chemically or recombinantly linked to a cytotoxic component. A number of different immunotoxins (IT) have increasingly been evaluated for immunotherapy. Since these foreign proteins are highly immunogenic in human, we have developed recombinant IT using the human ribonuclease angiogenin. Due to their potential toxic effects on eucaryotic cells, these IT are usually expressed in bacteria. Depending on the structure, size, and sequence of the desired IT, bacterial expression can be limited and the yield after purification be unsatisfactory. Therefore, the expression of IT in eucaryotic cells could provide a promising alternative. For this purpose we genetically fused the anti-CD30 single-chain variable fragment (scFv) Ki4 to the N- and C-termini of recombinant angiogenin. Both IT possess leader sequences, which mediate their secretion into the cell culture supernatant. Using a bicistronic mRNA the IT were simultaneously expressed together with enhanced green fluorescent protein (EGFP). This allows direct monitoring of transfected cells. An additional plasmid encoded Zeocin resistance enhances the cultivation of transfected cells under selection pressure. Three days after transfection of 293T-cells, unpurified IT were analyzed by flow cytometry and competitive cell proliferation assays. This is the first report on the use of eucaryotic cells for the secretion of functionally active IT with a human effector domain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699683     DOI: 10.1016/s1046-5928(02)00709-x

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  19 in total

1.  Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion protein.

Authors:  Stephanie Kapelski; Melanie de Almeida; Rainer Fischer; Stefan Barth; Rolf Fendel
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

2.  Cloning murine antibody V-genes with non-degenerate primers and conversion to a recombinant antibody format.

Authors:  Magdalena Bialon; Ludmila Schellenberg; Nicolas Herzog; Stefan Kraus; Hannah Jörißen; Rainer Fischer; Christoph Stein; Jörg Nähring; Stefan Barth; Christiane Püttmann
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-12

3.  In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.

Authors:  Judith Niesen; Hannes Brehm; Christoph Stein; Nina Berges; Alessa Pardo; Rainer Fischer; Andre Ten Haaf; Stefan Gattenlöhner; Mehmet K Tur; Stefan Barth
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

4.  SNAP-Tag Technology: A Promising Tool for Ex Vivo Immunophenotyping.

Authors:  Swati Choudhary; Stefan Barth; Rama S Verma
Journal:  Mol Diagn Ther       Date:  2017-06       Impact factor: 4.074

5.  Expression, purification, bioactivity, and partial characterization of a recombinant human bone morphogenetic protein-7 produced in human 293T cells.

Authors:  J C Bustos-Valenzuela; E Halcsik; E J Bassi; M A Demasi; J M Granjeiro; M C Sogayar
Journal:  Mol Biotechnol       Date:  2010-10       Impact factor: 2.695

6.  Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.

Authors:  Maulik Vyas; Ann-Charlott Schneider; Olga Shatnyeva; Katrin S Reiners; Samir Tawadros; Stephan Kloess; Ulrike Köhl; Michael Hallek; Hinrich P Hansen; Elke Pogge von Strandmann
Journal:  Oncoimmunology       Date:  2016-07-15       Impact factor: 8.110

7.  Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen.

Authors:  Katrin S Reiners; Hinrich P Hansen; Anne Krüssmann; Gisela Schön; Elena Csernok; Wolfgang L Gross; Andreas Engert; Elke Pogge Von Strandmann
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

8.  Recombinant bovine uteroglobin at 1.6 A resolution: a preliminary X-ray crystallographic analysis.

Authors:  Victoria von der Decken; Heinrich Delbrück; Andreas Herrler; Henning M Beier; Rainer Fischer; Kurt M V Hoffmann
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-04-22

9.  Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.

Authors:  Xiaojing Cong; Christian Cremer; Thomas Nachreiner; Stefan Barth; Paolo Carloni
Journal:  Protein Sci       Date:  2016-05-19       Impact factor: 6.725

10.  Development of a recombinant antibody to target peptides and proteins to sialoadhesin-expressing macrophages.

Authors:  Karen Ooms; Hanne Van Gorp; Tim Van Gaever; Hans J Nauwynck; Peter L Delputte
Journal:  BMC Biotechnol       Date:  2013-04-10       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.